Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pyrazole: preclinical reassessment.

P J O'Dwyer1, S A King, J Plowman

  • 1Fox Chase Cancer Center, Philadelphia, PA 19111.

Investigational New Drugs
|December 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Abstracts of presentations to the Annual Meetings of the Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons Canadian Hepato-Pancreato-Biliary Society Canadian Society of Surgical Oncology Canadian Society of Colon and Rectal Surgeons: Victoria, BC Sept. 10-13, 2009.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Characterisation of white and black merino wools: a proteomics study.

Animal : an international journal of animal bioscience·2018
Same author

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Reply to letter to the editor 'Primum non nocere' by Templeton and Šeruga.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same journal

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study.

Investigational new drugs·2026
Same journal

Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database.

Investigational new drugs·2026
Same journal

Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes.

Investigational new drugs·2026
Same journal

Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia.

Investigational new drugs·2026
Same journal

Correction to: Prostate cancer cells' growth is decreased by novel MYC inhibitors.

Investigational new drugs·2026
Same journal

Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330.

Investigational new drugs·2026
See all related articles

Pyrazole, a compound known for inhibiting alcohol dehydrogenase, shows potential as an anticancer agent. Its selective toxicity to thyroid tissue warrants further investigation for cancer treatment applications.

Area of Science:

  • Pharmacology
  • Oncology
  • Medicinal Chemistry

Background:

  • Pyrazole is a heterocyclic compound discovered in 1893.
  • Historically known as an inhibitor of liver alcohol dehydrogenase.
  • Identified for preclinical antitumor activity in 1960, leading to early clinical trials.

Purpose of the Study:

  • To review evidence on pyrazole's potential as an anticancer agent.
  • To address the historical omission of evaluating pyrazole's clinical anticancer activity.
  • To explore pyrazole's selective toxicity to thyroid tissue for targeted cancer therapy.

Main Methods:

  • Review of accumulated evidence on pyrazole.
  • Analysis of preclinical antitumor data.
  • Examination of pyrazole's selective toxicity in animal models.

Related Experiment Videos

Main Results:

  • Pyrazole demonstrated activity in preclinical antitumor models.
  • Early Phase I clinical studies were conducted but not followed by Phase II trials.
  • Pyrazole exhibits selective toxicity to thyroid tissue in animal models.

Conclusions:

  • Pyrazole's anticancer potential was never fully evaluated clinically.
  • Renewed interest stems from historical omissions and its selective tissue toxicity.
  • Further research is warranted to explore pyrazole for treating specific malignancies, particularly thyroid cancer.